Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03503344 · ClinicalTrials.gov registry record · Phase 2
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03503344 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 26 participants.
The verdict
NCT03503344, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving apalutamide with or without stereotactic body radiation therapy works better in treating participants with castration-resistant cancer.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Apalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03503344
The ClinicalTrials.gov registry entry for NCT03503344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT03503344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03503344 about?
NCT03503344 is a clinical study titled "Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer". This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by...
What is the current status of trial NCT03503344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-12-17. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT03503344?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Apalutamide (DRUG).
Who is sponsoring clinical trial NCT03503344?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.